Results 1 to 10 of about 4,865 (116)
Impact of Concomitant Metamizole Treatment on the Exposure of Mould-Active Triazoles. [PDF]
MycosesABSTRACT Aim Metamizole is an analgesic drug with moderate cytochrome P450 (CYP) inductive properties. The antifungal triazoles are metabolized by several CYP enzymes, but the interaction with metamizole remains poorly described. We investigated the influence of metamizole on the exposure of voriconazole, isavuconazole, and posaconazole.
Vanneste D +12 more
europepmc +2 more sources
British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2723-2740, August 2026.Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga +20 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 7, July 2026.ABSTRACT Therapeutic response in refractory invasive pulmonary aspergillosis may depend not only on antifungal class escalation, but also on formulation choice. In this complex pediatric acute myeloid leukemia (AML) case, radiologic improvement followed combination therapy and switch to brand‐name liposomal amphotericin B, underscoring the importance ...
Faryal Khamis +3 more
wiley +1 more source
Mycoses, Volume 69, Issue 7, July 2026.ABSTRACT Background The black moulds comprising Aspergillus section Nigri are clinically important organisms causing aspergillosis and otomycosis; triazole (azole) antifungal agents represent the primary prophylaxis and treatment option for these infections.
John H. Kimbrough +4 more
wiley +1 more source
Mycoses, Volume 69, Issue 7, July 2026.ABSTRACT Background Immunocompromised children with hematologic malignancies or undergoing allogeneic haematopoietic stem cell transplantation (HSCT) are at high risk for invasive fungal diseases (IFDs). Reported incidence varies considerably due to heterogeneous diagnostic criteria, antifungal strategies and environmental conditions.
Stefano Malvestiti +6 more
wiley +1 more source
An Update on Invasive Fungal Infections in Solid Organ Transplant Recipients
Transplant Infectious Disease, Volume 28, Issue 4, July/August 2026.ABSTRACT Invasive fungal infections (IFI) remain a significant infection‐related complication in solid organ transplant recipients (SOTRs), the incidence of which has not changed overtime. With a focus on studies and data published after 2019, this narrative review provides an update on the epidemiology and prevention of IFIs in SOTRs and highlights ...
Tina Marinelli, Shahid Husain
wiley +1 more source
Peer review of the pesticide risk assessment of the active substance Trichoderma atroviride 77B
EFSA Journal, Volume 24, Issue 7, July 2026.Abstract The conclusions of the EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, the Netherlands, for the pesticide active substance Trichoderma atroviride 77B and the considerations as regards the inclusion of the substance in Annex IV of Regulation (EC) No 396/2005 ...
European Food Safety Authority (EFSA) +48 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Checkpoint inhibitor‐associated pneumonitis complicated by invasive pulmonary aspergillosis represents a diagnostic challenge in ICI‐treated patients, particularly those with COPD receiving corticosteroid therapy. Persistent or worsening respiratory abnormalities despite immunosuppressive treatment should prompt reassessment for superimposed ...
Chukwuka Elendu +3 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Cutaneous mucormycosis is a rare invasive fungal infection caused by fungi of the order Mucorales. Although it classically occurs in immunocompromised hosts, traumatic or minor cutaneous inoculation may result in infection even in patients without active immunosuppression.
Akın Öğünç İnan +5 more
wiley +1 more source